Cargando…
Epigenetic based synthetic lethal strategies in human cancers
Over the past decades, it is recognized that loss of DNA damage repair (DDR) pathways is an early and frequent event in tumorigenesis, occurring in 40-50% of many cancer types. The basis of synthetic lethality in cancer therapy is DDR deficient cancers dependent on backup DNA repair pathways. In can...
Autores principales: | Gao, Aiai, Guo, Mingzhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493427/ https://www.ncbi.nlm.nih.gov/pubmed/32974031 http://dx.doi.org/10.1186/s40364-020-00224-1 |
Ejemplares similares
-
Epigenetic heterogeneity in cancer
por: Guo, Mingzhou, et al.
Publicado: (2019) -
Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
por: Hu, Yunlong, et al.
Publicado: (2020) -
Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
por: Du, Wushuang, et al.
Publicado: (2021) -
Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019) -
Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)